Method of treating pain by administering 24 hour oral opioid formulations
Patent 5672360 Issued on September 30, 1997. Estimated Expiration Date: July 22, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.
Other References
A protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol.RTM. to Ms Contin.RTM. in the Management of Patients with Moderate to Severe Cancer Pain" (the Protocol). The date of the Protocol is indicated as Feb. 10, 1992 and it bears CDD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, an Australian company
Certain Patient Diary Cards, Drug Disposition Records, Case Report Forms and a listing which apparently correlates patient randomization number with the treatment or dosing regiment assigned to each patient
Patient consent forms, apparently for four study participants
Certain documents regarding Institutional Review Board Approval for the Faulding-sponsored study
Investigator Agreements between the study organizers and certain of the principal investigators
R. Kaiko and T. Hunt, "Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulations in Healthy Young Adults", Clin. Thera., vol. 13, No. 4, 1991
R. West and C. Maccarrone, "Single Dose Pharmacokinetics of a New Oral Sustained-Release Morphine Formulation, Kapanol.RTM. Capsules", Abstracts--7th World Congress on Pain, Aug. 26, 1993, Abstracts 997-1001
S. Bloomfield, et al., "Analgesic efficacy and potency of two oral controlled-release morphine preparations", Clin. Pharmacol. Ther., vol. 53, No. 4, pp. 469-478, .COPYRGT.1993
Advertisement: MS Contin.RTM., .COPYRGT.1986, 1987, The Purdue Frederick Company
Abraham Sunshine, et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain", Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746
E. Beubler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken", Therapiewoche Osterreich, 7,2 (1992), pp. 90-96, with English translation
Geoffrey K. Gourlay, Ph.D., et al., "Influence of a high-fat meal on the absorption of morphine from oral solutions", Clin. Pharmacol. Ther., Oct. 1989, pp. 463-468
Robert Kaiko, et al., "A Single-Dose Study Of The Effect Of Food Ingestion And Timing Of Dose Administration On The Pharmacokinetic Profile Of 30-MG Sustained-Release Morphine Sulfate Tablets", Current Therapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878
Geoffrey K. Gourlay, Ph.D., "The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions", Journal of Pain and Sympton Management, vol. 6, No. 7, Oct. 1991, pp. 431-436
Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food", The Hospice Journal, vol. 6(4) 1990, pp. 17-30
N. Yokokawa, et al., "Relationship between plasma concentration of morphine and analgesic effectiveness", Postgrad Med J, (1991) 67 (Suppl. 2) pp. 550-554
Physicians Desk Reference 1994, 48th Edition, pp. 1821-1824
Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987
J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation", Journ. of Pain and Sympton Manag., v 4 (3), pp. 146-151, 198
J. Lapin et al., "Guidelines for use of Controlled Release Oral Morphine in Cancer Pain Management", Cancer Nursing, v 12 (4), pp. 202-208, 1989
R.F. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets):A Review of the Published Literature", Medical Department, The Purdue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989)
H.F. Slowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain", Anaesthesia, 1985, vol. 40, pp. 438-440
MS Contin--Frequency of Daily Dosing, Jan.-Nov. 1990
R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Kapanol.RTM. Capsules Given Every 24 hours and Every 12 hours with MS Contin.RTM. Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain
July 22, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
